Therapeutic Workshop Details
Cancer: Turning the Heat Up on Cancer - New Technologies to Enhance Antibodies
Thursday, October 11, 2007
8:15 AM
Twin Peaks South
Antibodies or immunoglobulins are a crucial component of the immune system, circulating in the blood and lymphatic system, and binding to foreign antigens expressed on cells. Monoclonal antibodies achieve their therapeutic effect through various mechanisms, find out about the new technologies that are changing the way we treat cancer.
Moderators
- Jason Kantor, PhD; Managing Director and Senior Biotechnology Analyst, RBC Capital Markets
Panelists
- Bassil I. Dahiyat; President and Chief Executive Officer, Xencor, Inc.
- Christian Itin, PhD; President, Chief Executive Officer and Director, Micromet Inc.
- Daniel M. Junius; Chief Financial Officer and Executive Vice President, Finance, ImmunoGen
- Nils Lonberg, PhD; Senior Vice President and Scientific Director, Medarex, Inc.
Who's Who
Dr. Kantor joined RBC Capital Markets in 2005 as a managing director and senior biotechnology equity research analyst. Previously, he was a managing director and senior biotechnology analyst at WR Hambrecht + Co from 2002 to 2005, and vice president in equity research at J.P. Morgan Chase & Co from 1998 to 2002. Previous equity research assignments also include Salomon Smith Barney and Josephthal Lyon & Ross. Dr. Kantor's healthcare expertise covers several important categories including oncology, cardiology, antibody technology and infectious disease. In 2004, Fortune magazine ranked Dr. Kantor as an "All-Star Analyst," and the Wall Street Journal ranked him #2 in its "Best on Wall Street Survey." Dr. Kantor received his B.A. cum laude in Biology from the University of California, San Diego and his Ph.D. in Cell and Developmental Biology from Harvard University.